health news arrowHome >> Drugs & Herbs >> Blood Clotting Drug Dramatically Improves Outcomes for Severe Stroke Victims Fri, 16 May 2008 GMT 
health news
  NEWS YOU CAN TRUST

Search Health News 
Browser Preferences
 Add to Favorites

Main Menu
 Home
 - - - - - Hot Topics - - - - -
 Bird Flu
 Drug Safety
 Stem Cell Research
 - - - - - - - - - - - - - - - - -
 Alternative Medicine
 Children's Health
 Diet & Nutrition
 Disabilities
 *Diseases & Conditions
 Drugs & Herbs
 Environmental Health
 Fitness & Exercise
 Genetic Research
 Health Insurance
 Medical Ethics
 Men's Health
 *Mental Illness
 Pain
 Parenting
 Public Health & Safety
 Senior Care
 *Sexual Health
 Women's Health
 World Health
 - - - - - - - - - - - - - - - -
 Web Links
 Contact Us: info@dailynewscentral.com

XML News Feeds


 

HEALTH NEWS

Blood Clotting Drug Dramatically Improves Outcomes for Severe Stroke Victims

PDF  Print  E-mail
Contributed by Ron Gara|  22 February, 2005  22:55 GMT

bleeding stroke hemophilia drug
Investigators were stunned to find that reducing bleeding in the brain by just one teaspoon of blood improved the chances of patient survival by nearly 40 percent.
Study participants who took a drug commonly prescribed for hemophilia to treat a severe type of stroke experienced reduced bleeding in the brain, fewer deaths, and better neurological and clinical outcomes than patients who received a placebo. The lead investigator in the study termed the results "stunning."

The multi-center, international study, led by Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, shows that recombinant activated factor VII (rFVIIa) has the potential to be a significant advance in treating bleeding stroke (acute intracerebral hemorrhage, or ICH).

The work is published in the February 24 issue of the New England Journal of Medicine.

Current Treatments Not Effective

ICH is the deadliest and most disabling type of stroke -- more than one out of three ICH patients die within one month of onset and only 20% regain functional independence. Physicians have long been frustrated by a lack of effective therapies to improve survival outcomes or recovery; current options are only supportive.

RFVIIa currently is entering phase III trials as an investigational treatment for ICH. If approved by the U.S. Food and Drug Administration, it will become only the second emergency treatment for stroke in more than three decades. The first was TPA, approved by the FDA in 1996.

“Current medical and surgical options for ICH are not effective. Thirty-five to 50 percent of patients die within one month, and if they survive, they live with serious neurological deficits. Current data suggest a possible change in our paradigm for the treatment of ICH,” says Stephan A. Mayer, M.D., the study's principal investigator. Dr. Mayer is an associate professor of neurology and neurosurgery at Columbia University College of Physicians and Surgeons, and director of the Neurological Intensive Care Unit at NewYork-Presbyterian Hospital/Columbia.

Stunning Results

“I approached this study with modest expectations, expecting to see some trends toward improved outcomes,” notes Dr. Mayer. “I was stunned to find that by preventing just 5 ml of additional blood -- about one teaspoon -- of bleeding in the brain, we were able to increase chances of patient survival by nearly 40%.”

The third highest cause of death in the United States, stroke is the leading source of permanent disability, resulting in significant worsening of quality of life for patients and costing billions of dollars to society. ICH affects 15% of all stroke victims in the U.S. -- about 70,000 cases a year. In other parts of the world, the incidence of bleeding stroke is even higher. In Asia, ICH affects 30% of all stroke victims.

With 73 sites in 20 countries, this study represents the largest clinical trial ever conducted with a pharmacologic agent for the treatment of ICH. As a physician treating patients over many years with this deadly form of stroke, Dr. Mayer decided to investigate rFVIIa as a treatment for ICH after reading about its coagulation effects. With the brand name "NovoSeven," rFVIIa has been on the U.S. market since 1999 as a treatment for hemophilia, and is manufactured by Novo Nordisk.

Related Articles
Taking Aspirin May Be Too Risky for Some Seniors (21 May 2005)
Aspirin's Risks May Outweigh Benefits for Elderly (20 May 2005)
Lipitor Lowers Risk of Second Stroke (11 Aug 2006)
Hormone Replacement Therapy Connected to Stroke Risk (9 Jan 2005)
Aspirin Safer Than Warfarin for Reducing Stroke Risk (31 Mar 2005)
Canadian Red Cross Apologizes for Tainted-Blood Calamity (31 May 2005)
 
Sponsored Text Links
SkinStore.com: StriVectin-SD
InsureMe.com: Click here to get a free health insurance quote.
SkinStore.com: Strivectin SD 6oz Best Price Offer
Hydroderm: Lose wrinkles with Hydroderm
Hydroderm: Body Shape - Proven to be safe and effective - Free Trial!